HC Wainwright Issues Positive Outlook for Compugen Earnings

Compugen Ltd. (NASDAQ:CGEN) – Equities researchers at HC Wainwright raised their FY2026 earnings per share estimates for Compugen in a report released on Tuesday, August 4th. HC Wainwright analyst S. Ramakanth now forecasts that the biotechnology company will post earnings per share of ($0.35) for the year, up from their prior estimate of ($0.38). HC Wainwright has a “Buy” rating on the stock. The consensus estimate for Compugen’s current full-year earnings is ($0.28) per share. HC Wainwright also issued estimates for Compugen’s Q3 2027 earnings at ($0.10) EPS, Q4 2027 earnings at ($0.10) EPS, FY2027 earnings at ($0.41) EPS, FY2028 earnings at ($0.43) EPS, FY2029 earnings at ($0.44) EPS and FY2030 earnings at ($0.29) EPS.

CGEN has been the subject of a number of other reports. Leerink Partners lowered their price objective on Compugen from $13.00 to $5.00 and set an “outperform” rating for the company in a research report on Thursday, May 21st. Wall Street Zen cut shares of Compugen from a “buy” rating to a “hold” rating in a report on Saturday, May 23rd. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Compugen in a research note on Friday, July 17th. One equities research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $5.00.

Compugen Price Performance

CGEN stock opened at $2.28 on Thursday. The business’s 50-day moving average is $2.24 and its two-hundred day moving average is $2.27. The firm has a market capitalization of $215.58 million, a P/E ratio of 6.00 and a beta of 2.77. Compugen has a 1 year low of $1.29 and a 1 year high of $3.23.

Compugen (NASDAQ:CGEN) last released its earnings results on Monday, August 3rd. The biotechnology company reported ($0.07) EPS for the quarter, topping the consensus estimate of ($0.08) by $0.01. Compugen had a return on equity of 42.57% and a net margin of 47.56%.The firm had revenue of $2.60 million during the quarter, compared to analysts’ expectations of $1.28 million. During the same period in the previous year, the firm posted ($0.08) EPS.

Institutional Investors Weigh In On Compugen

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Jane Street Group LLC increased its position in shares of Compugen by 1,077.0% during the second quarter. Jane Street Group LLC now owns 393,191 shares of the biotechnology company’s stock worth $700,000 after purchasing an additional 359,785 shares in the last quarter. Renaissance Technologies LLC lifted its holdings in shares of Compugen by 12.1% in the 1st quarter. Renaissance Technologies LLC now owns 1,632,988 shares of the biotechnology company’s stock valued at $3,478,000 after purchasing an additional 176,088 shares during the last quarter. XTX Topco Ltd acquired a new stake in shares of Compugen in the 4th quarter valued at about $104,000. Marshall Wace LLP boosted its position in shares of Compugen by 135.7% in the 4th quarter. Marshall Wace LLP now owns 106,304 shares of the biotechnology company’s stock valued at $163,000 after purchasing an additional 61,202 shares during the period. Finally, WINTON GROUP Ltd purchased a new position in Compugen during the 4th quarter worth approximately $84,000. 12.22% of the stock is currently owned by institutional investors and hedge funds.

About Compugen

Compugen Ltd. (NASDAQ: CGEN) is a clinical-stage therapeutic discovery company that leverages proprietary computational discovery platforms to identify novel immuno-oncology targets and biomarkers. The company combines large-scale biological datasets with machine learning algorithms to generate and validate new therapeutic and diagnostic candidates. Founded in 1993 and headquartered in Tel Aviv, Israel, Compugen also maintains a presence in the United States to support its clinical development and commercial collaborations.

Compugen’s predictive discovery engine scans complex biological systems in silico to reveal previously unrecognized pathways and immune checkpoints involved in cancer progression.